Latest Board Governance News

Bapcor reports a softer FY25 with pro-forma NPAT of $81-82 million and statutory NPAT sharply lower at $31-34 million, citing operational disruptions and a challenging retail environment. The company also announces key board resignations amid a strategic reset.

Universal Biosensors has signed a non-binding term sheet for an A$8.5 million senior secured loan with Viburnum Funds, alongside plans for an equity raising. The move comes with governance shifts, including a director resignation to avoid conflicts.

Southern Cross Media Group has finalized the sale of its remaining television assets, fully committing to its 'All About Audio' strategy with a 5% rise in audio revenues for FY25 and a renewed focus on debt reduction and dividends.

Epsilon Healthcare and its subsidiaries have officially exited voluntary administration and Deeds of Company Arrangement, marking a pivotal recovery milestone supported by significant personal commitments from the new board. The company now shifts focus to strategic growth and rebuilding trust.

Vulcan Steel announces a significant leadership transition with CEO Rhys Jones retiring after nearly two decades, handing the reins to Gavin Street from January 2026. The board reshuffle also sees Jones moving to non-executive Chair, ensuring continuity at the top.

Lovisa Holdings has appointed John Cheston as Global CEO and Managing Director, alongside Mark McInnes as Executive Deputy Chairman, signaling a strategic push for global growth.

Wingara AG Limited’s planned funding placement with Terra Firma Equity Limited has fallen through, prompting legal considerations and a pause on a key board appointment.

IVE Group Limited has scheduled its half-year financial results release for February 24, 2025, alongside a notable governance change with Paul Selig moving from Executive to Non-Executive Director.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.